Hugh has made over 1 trades of the Puma Biotechnology Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 18,868 units of PBYI stock worth $50,000 on 20 August 2018.
The largest trade he's ever made was exercising 18,868 units of Puma Biotechnology Inc stock on 20 August 2018 worth over $50,000. On average, Hugh trades about 1,887 units every 0 days since 2018. As of 20 August 2018 he still owns at least 445,868 units of Puma Biotechnology Inc stock.
You can see the complete history of Mr. dowd stock trades at the bottom of the page.
Hugh O Dowd serves as Independent Director of the Company. Since September 2016, Mr. O’Dowd has served as President, Chief Executive Officer and a member of the board of directors of Neon Therapeutics, Inc. a public clinical-stage immuno-oncology company developing neoantigen-based therapeutics. Prior to that, Mr. O’Dowd spent more than 20 years in a variety of leadership roles at Novartis Pharmaceuticals Corporation. While at Novartis, he served as Country President and General Manager of the United Kingdom and Ireland from 2015 to 2016, he was Senior Vice President and Chief Commercial Officer of Novartis Oncology from 2011 to 2015, and he served as Vice President, Latin America Region Head for the Oncology business unit from 2009 to 2011. During his time as Chief Commercial Officer, Mr. O’Dowd was responsible for the global commercialization of Novartis’ oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Mr. O’Dowd received an M.B.A. from the Kellstadt Graduate School of Business at DePaul University in Chicago and a B.A. from Loyola University Chicago. He was nominated to serve as a director because of his significant experience and leadership in the life sciences industry and, in particular, commercialization of oncology drugs.
As the Independent Director of Puma Biotechnology Inc, the total compensation of Hugh Dowd at Puma Biotechnology Inc is $461,937. There are 10 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
Hugh Dowd is 55, he's been the Independent Director of Puma Biotechnology Inc since 2019. There are 8 older and 5 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
Hugh's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo et Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: